This is especially critical for the cohorts (G1 and G3: WM, on BTKi-based or rituximab-based regimens; MM on anti-CD38 or anti-BCMA therapies) where most individuals (90% and 45%, respectively) have low or no NAb responses. Here, CD38 is linked to Miyoshi myopathy.